Universitat Jaume I-ko ikertzaileekin lankidetzan egindako argitalpenak (39)

2024

  1. Association between N-terminal pro-brain natriuretic peptide and maximal functional capacity in heart failure with preserved ejection fraction: The modifying role of obesity

    Obesity Research and Clinical Practice

  2. Exercise training response according to baseline ferrokinetics in heart failure with preserved ejection fraction: A substudy of the TRAINING-HF trial

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 15, Núm. 2, pp. 681-689

  3. Unraveling the Mechanisms Behind Exercise Intolerance and Recovery in Long COVID

    American Journal of Medicine

  4. β-Blocker Withdrawal and Functional Capacity Improvement in Patients with Heart Failure with Preserved Ejection Fraction

    JAMA Cardiology, Vol. 9, Núm. 4, pp. 392-396

2023

  1. A model-driven transformation approach for the modelling of processes in clinical practice guidelines

    Artificial Intelligence in Medicine, Vol. 137

  2. Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 511-518

  3. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  4. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 10, pp. 783-792

  5. Maximal functional capacity in subjects with isolated left bundle branch block: A pilot study

    Clinical Cardiology, Vol. 46, Núm. 4, pp. 386-389

  6. Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction

    Journal of Cardiac Failure, Vol. 29, Núm. 5, pp. 849-854

2022

  1. Beta-blockers and renin–angiotensin–aldosterone system inhibitors in HFpEF. An urgent need for precision medicine

    REC: CardioClinics, Vol. 57, Núm. 3, pp. 162-164

  2. Effect of a home-based inspiratory muscular training programme on functional capacity in patients with chronic COVID-19 after a hospital discharge: Protocol for a randomised control trial (InsCOVID trial)

    BMJ Open Respiratory Research, Vol. 9, Núm. 1

  3. Sex Effect in the Decision to Perform Invasive Coronary Angiography in Patients With Chronic Coronary Syndrome After Undergoing Vasodilator Stress MRI

    Journal of Magnetic Resonance Imaging, Vol. 56, Núm. 6, pp. 1680-1690

  4. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 10, pp. 1816-1826

2021

  1. Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure

    European Journal of Internal Medicine, Vol. 92, pp. 94-99

  2. Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

    Journal of the American College of Cardiology, Vol. 78, Núm. 21, pp. 2042-2056

  3. Evaluation of a novel biomarker of type XXVIII collagen formation, PRO-C28, in samples from cancer and heart failure with preserved ejection fraction patients

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 204

  4. Iron deficiency and short-term adverse events in patients with decompensated heart failure

    Clinical Research in Cardiology, Vol. 110, Núm. 8, pp. 1292-1298

  5. Matrix metalloproteinase-12 cleaved fragment of titin as a predictor of functional capacity in patients with heart failure and preserved ejection fraction

    Scandinavian Cardiovascular Journal, Vol. 55, Núm. 1, pp. 9-14

2020

  1. Beta-blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve-HR trial)

    Clinical Cardiology, Vol. 43, Núm. 5, pp. 423-429